<code id='C1455312F8'></code><style id='C1455312F8'></style>
    • <acronym id='C1455312F8'></acronym>
      <center id='C1455312F8'><center id='C1455312F8'><tfoot id='C1455312F8'></tfoot></center><abbr id='C1455312F8'><dir id='C1455312F8'><tfoot id='C1455312F8'></tfoot><noframes id='C1455312F8'>

    • <optgroup id='C1455312F8'><strike id='C1455312F8'><sup id='C1455312F8'></sup></strike><code id='C1455312F8'></code></optgroup>
        1. <b id='C1455312F8'><label id='C1455312F8'><select id='C1455312F8'><dt id='C1455312F8'><span id='C1455312F8'></span></dt></select></label></b><u id='C1455312F8'></u>
          <i id='C1455312F8'><strike id='C1455312F8'><tt id='C1455312F8'><pre id='C1455312F8'></pre></tt></strike></i>

          knowledge

          knowledge

          author:leisure time    Page View:45472
          John Thune raises one hand while speaking to the press at the Capitol 2024 — politics coverage from STAT
          Sen. John Thune is one of a group of lawmakers that is working on 340B reform legislation. BRENDAN SMIALOWSKI/AFP via Getty Images

          WASHINGTON — A bipartisan group of senators released a draft of legislation to resolve controversial disputes in the 340B drug discount program, according to documents obtained by STAT.

          The drug discount program, which was designed to support providers that serve low-income patients, has been increasingly contentious as it’s grown in recent years. The draft legislation makes a number of changes to address some of the most controversial points, including its rules over so-called “contract pharmacies” and which subsidiaries can qualify for discounts.

          advertisement

          The draft would also require more oversight, and it would give the Health Resources and Services Administration more money to do it with a new user fee program. Providers would pay HRSA up to 0.1% of the savings it receives from the program.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation
          Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

          1:30WashingtonCommandersownersDanSnyderonthefieldbeforetheDallasCowboysdefeatoftheWashingtonCommande

          read more
          Wildfire smoke exposes gaps in outdoor worker protections
          Wildfire smoke exposes gaps in outdoor worker protections

          ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

          read more

          Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

          MollyFerguson/STATThisweek,apreviewoftheTUDCAstudyinALSandthoughtsonhowitmightimpactAmylyxPharmaceut